We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+18.95%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$11.5B
AUM Growth
+$2.07B
Cap. Flow
+$618M
Cap. Flow %
5.37%
Top 10 Hldgs %
60.42%
Holding
101
New
16
Increased
10
Reduced
10
Closed
17

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$799M
2
COAG
Hemab Therapeutics
COAG
+$215M
3
ABVX
Abivax
ABVX
+$128M
4
ORKA
Oruka Therapeutics
ORKA
+$104M
5
ARTV
Artiva Biotherapeutics
ARTV
+$73.8M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$219M
2
NUVL
Nuvalent
NUVL
+$138M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$120M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$84.9M
5
SYRE icon
Spyre Therapeutics
SYRE
+$81.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Financials 0.27%
3 Miscellaneous 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCSC
76
DELISTED
Perceptive Capital Solutions
PCSC
$8.16M 0.07%
750,000
– –
ACET icon
77
Adicet Bio
ACET
$84.8M
$8.06M 0.07%
932,624
-250,000
-21% -$1.97M
NAMSW icon
78
NewAmsterdam Pharma Warrant
NAMSW
$7.12M 0.06%
333,333
– –
CRVS icon
79
Corvus Pharmaceuticals
CRVS
$1.19B
$6.72M 0.06%
450,000
– –
RANI icon
80
Rani Therapeutics
RANI
$97M
$6.46M 0.06%
8,500,000
– –
JATT
81
JATT II Acquisition Corp
JATT
$93.6M
$5.68M 0.05%
+500,000
New +$5.31M
AMAN
82
Amanat Acquisition Corp
AMAN
$104M
$3.81M 0.03%
+375,000
New +$3.79M
HOWL icon
83
Werewolf Therapeutics
HOWL
$45.8M
$859K 0.01%
2,387,744
-4,293,563
-64% -$2.62M
PTN
84
Palatin Technologies
PTN
$18.6M
$670K 0.01%
62,124
-7,876
-11% -$130K
DNTH icon
85
Dianthus Therapeutics
DNTH
$5.92B
– –
-2,611,733
Closed -$219M
DSGN icon
86
Design Therapeutics
DSGN
$946M
– –
-2,972,973
Closed -$31.6M
FULC icon
87
Fulcrum Therapeutics
FULC
$294M
– –
-6,053,960
Closed -$46.4M
INSP icon
88
Inspire Medical Systems
INSP
$1.78B
– –
-325,663
Closed -$16.8M
OLMA icon
89
Olema Pharmaceuticals
OLMA
$899M
– –
-2,600,000
Closed -$38.8M
PRAX icon
90
Praxis Precision Medicines
PRAX
$9.63B
– –
-373,787
Closed -$120M
RLMD icon
91
Relmada Therapeutics
RLMD
$462M
– –
-2,947,369
Closed -$20.5M
SRPT icon
92
Sarepta Therapeutics
SRPT
$2.2B
– –
-3,902,596
Closed -$84.9M
STRO icon
93
Sutro Biopharma
STRO
$339M
– –
-715,307
Closed -$17.8M
SYRE icon
94
Spyre Therapeutics
SYRE
$7.97B
– –
-1,621,620
Closed -$81.8M
TVTX icon
95
Travere Therapeutics
TVTX
$6.19B
– –
-746,841
Closed -$22.2M
WGS icon
96
GeneDx Holdings
WGS
$2.57B
– –
-209,887
Closed -$13.5M
CTNM
97
Contineum Therapeutics
CTNM
$641M
– –
-1,296,012
Closed -$16.9M
GRAL
98
GRAIL Inc
GRAL
$3.57B
– –
-428,266
Closed -$22.1M
HNGE
99
Hinge Health
HNGE
$7.05B
– –
-364,613
Closed -$14.1M
MPLT
100
MapLight Therapeutics
MPLT
$584M
– –
-248,294
Closed -$5.05M
1 2 3
4
5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, RA Capital Management held 101 positions worth $11.5B, up 22% from $9.44B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

RA Capital Management deployed $618M of net new capital in Q2 2026, opening 16 new positions and adding to 10 existing holdings. Its largest new stake was Parabilis Medicines Inc: 28,933,371 shares worth $792M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Nuvalent, an estimated $138M trimmed.

  • RA Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 28,933,371 shares worth $792M.
  • RA Capital Management added most to Artiva Biotherapeutics in Q2 2026, an estimated $73.8M increase.
  • RA Capital Management's biggest Q2 2026 reduction was Nuvalent, cutting an estimated $138M.
  • RA Capital Management fully exited Dianthus Therapeutics in Q2 2026, selling an estimated $219M.
  • RA Capital Management's ten largest holdings make up 60% of its $11.5B portfolio in Q2 2026.
  • RA Capital Management opened 16 new positions and closed 17 in Q2 2026.
  • RA Capital Management's portfolio value rose 22% quarter-over-quarter to $11.5B.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.